A Complete Response Letter (CRL) from the FDA due to manufacturing issues can destroy a biotech. CEO Ron Cooper warns leaders to invest heavily in Chemistry, Manufacturing, and Controls (CMC) early, even when the cost exceeds the clinical trial spend. This early investment in professionalizing CMC is critical to de-risk the company's future.

Fears of regulatory hurdles for new manufacturing platforms may be overstated. Regulators, familiar with technologies like molecular farming for decades, prioritize the final product's purity, safety, and efficacy. The platform's novelty is secondary to robust scientific data proving the end product's quality.

Failing to conduct comprehensive screening for strain selection and media development at the project's start creates issues that become significantly more difficult and expensive to resolve later. Small, early-stage problems can derail downstream processing and scale-up efforts entirely.

Dealing with regulatory bodies can be terrifying, especially for a startup facing a recall. The key is to present objective facts, demonstrate a rigorous process, and make decisions that protect the product and patient. This builds trust and ensures long-term viability.

For early-stage biotech companies, saving money by limiting initial drug substance characterization is a false economy. A comprehensive, state-of-the-art characterization before Phase 1 is essential to de-risk the program by identifying molecular issues before they become catastrophic problems in late-stage development.

In polymerization processes like DNA synthesis, not all impurities are equal. Bifunctional impurities, which can react at two points, are especially harmful because their disruptive effect is multiplicative as they get incorporated into the polymer chain. This means even trace amounts below 0.1% can ruin an entire batch.

An FDA analysis of Complete Response Letters (CRLs) since 2020 revealed that 70% of drug approval rejections were due to CMC issues. This data underscores that manufacturing and control strategies are a primary gatekeeper for regulatory approval, not just clinical trial results.

The dangerous nitrosamine (NDMA) in Zantac wasn't a pre-existing manufacturing contaminant. The active drug, ranitidine, chemically degraded to form the carcinogen. This finding, which corrected the FDA's initial assessment, shows that a drug itself can be the source of its own toxicity, a critical distinction for risk analysis.

The FDA's inconsistency and the growing gap between its guidance and actions have made regulatory risk a primary evaluation factor for investors, complicating trial design, causing delays, and raising the cost of capital for biotechs.